Ivor Elrifi Biography and Net Worth

Chief Executive Officer and Executive Director of Tiziana Life Sciences

Ivor Elrifi serves as our Chief Executive Officer and Executive Director. Mr Elrifi was formerly the global head of the Patent Group at Cooley since 2014 and before that the global head of Patents at Mintz Levin from 1999 – 2014. He has counseled companies in various key industries, including pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, universities, hospitals and governments throughout the world, particularly in the US and Europe. Ivor has guided clients in developing and implementing intellectual property strategies and in the prosecution, licensing and enforcement of patents. He has extensive experience in advising clients on strategic transactional work and regularly counsels’ clients with respect to investments, business development and mergers and acquisitions, including acquisition transactions involving Novartis, Eli Lilly, Biogen and Astellas.

He has received various awards throughout his career, including being named an “LMG Life Sciences: Life Science Star,” and ranked nationally in Chambers USA since 2007. Elrifi earned his B.S. and Ph.D. in Biology from Queen’s University and his J.D. from Osgoode Hall Law School.

What is Ivor Elrifi's net worth?: The estimated net worth of Ivor Elrifi is at least $5.06 million as of August 4th, 2026. Mr. Elrifi owns 4,556,068 shares of Tiziana Life Sciences stock worth more than $5,057,235 as of August 26th. This net worth approximation does not reflect any other investments that Mr. Elrifi may own. Learn More about Ivor Elrifi's net worth.
How do I contact Ivor Elrifi?: The corporate mailing address for Mr. Elrifi and other Tiziana Life Sciences executives is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. Tiziana Life Sciences can also be reached via phone at 44-20-7495-2379 and via email at [email protected]. Learn More on Ivor Elrifi's contact information.
Has Ivor Elrifi been buying or selling shares of Tiziana Life Sciences?: Within the last three months, Ivor Elrifi has bought $985,908.79 of Tiziana Life Sciences stock. Most recently, on Wednesday, August 5th, Ivor Elrifi bought 237,616 shares of Tiziana Life Sciences stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $237,616.00. Following the completion of the transaction, the chief executive officer now directly owns 4,793,684 shares of the company's stock, valued at $4,793,684. Learn More on Ivor Elrifi's trading history.
Are insiders buying or selling shares of Tiziana Life Sciences?: During the last twelve months, Tiziana Life Sciences insiders bought shares 3 times. They purchased a total of 988,423 shares worth more than $985,908.79. The most recent insider tranaction occured on August, 5th when CEO Ivor Elrifi bought 237,616 shares worth more than $237,616.00. Insiders at Tiziana Life Sciences own 39.8% of the company. Learn More about insider trades at Tiziana Life Sciences.
Information on this page was last updated on 8/5/2026.

Ivor Elrifi Insider Trading History at Tiziana Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/5/2026	Buy	237,616	$1.00	$237,616.00	4,793,684
8/4/2026	Buy	83,807	$0.97	$81,292.79	4,556,068
8/3/2026	Buy	667,000	$1.00	$667,000.00	4,472,261

Ivor Elrifi Buying and Selling Activity at Tiziana Life Sciences

Tiziana Life Sciences Company Overview

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Today's Range

Now: $1.11

$1.10

$1.18

50 Day Range

MA: $1.10

$0.89

$1.33

2 Week Range

Now: $1.11

$0.87

$2.35

Volume

440,962 shs

Average Volume

1,149,673 shs

Market Capitalization

$141.26 million

P/E Ratio

N/A

Dividend Yield